Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease
M Noetzli, CB Eap - Clinical pharmacokinetics, 2013 - Springer
With the aging population and its rapidly increasing prevalence, dementia has become an
important public health concern in developed and developing countries. To date, the …
important public health concern in developed and developing countries. To date, the …
Why we need to take a closer look at genetic contributions to CYP3A activity
Q Zhai, M van der Lee, T van Gelder… - Frontiers in …, 2022 - frontiersin.org
Cytochrome P450 3A (CYP3A) subfamily enzymes are involved in the metabolism of 40% of
drugs in clinical use. Twin studies have indicated that 66% of the variability in CYP3A4 …
drugs in clinical use. Twin studies have indicated that 66% of the variability in CYP3A4 …
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
RC Hartkoorn, W San Kwan, V Shallcross… - Pharmacogenetics …, 2010 - journals.lww.com
Objective OATP1B1 and OATP1B3 are major hepatic drug transporters whilst OATP1A2 is
mainly located in the brain but is also located in liver and several other organs. These …
mainly located in the brain but is also located in liver and several other organs. These …
The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications
E Chigutsa, ME Visser, EC Swart, P Denti… - Antimicrobial agents …, 2011 - Am Soc Microbiol
Among patients with tuberculosis, rifampin plasma concentrations and sputum conversion
rates have been reported to be lower in Africans. Rifampin is a substrate of P-glycoprotein …
rates have been reported to be lower in Africans. Rifampin is a substrate of P-glycoprotein …
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing …
C Wyen, H Hendra, M Siccardi, M Platten… - Journal of …, 2011 - academic.oup.com
Abstract Objectives Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic
clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene …
clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene …
The role of drug transporters in the kidney: lessons from tenofovir
Tenofovir disoproxil fumarate, the prodrug of nucleotide reverse transcriptase inhibitor
tenofovir, shows high efficacy and relatively low toxicity in HIV patients. However, long-term …
tenofovir, shows high efficacy and relatively low toxicity in HIV patients. However, long-term …
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study
R Lubomirov, S Colombo, J di Iulio… - Journal of infectious …, 2011 - academic.oup.com
Background. Poor tolerance and adverse drug reactions are main reasons for
discontinuation of antiretroviral therapy (ART). Identifying predictors of ART discontinuation …
discontinuation of antiretroviral therapy (ART). Identifying predictors of ART discontinuation …
Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and …
J Svaerd, JP Spiers, F Mulcahy… - JAIDS Journal of …, 2010 - journals.lww.com
Background: Antiretroviral therapy including HIV protease inhibitors and nonnucleoside
reverse transcriptase inhibitors can both inhibit and induce expression of cytochrome P450s …
reverse transcriptase inhibitors can both inhibit and induce expression of cytochrome P450s …
Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-naive HIV-infected …
L Dickinson, J Amin, L Else, M Boffito, D Egan… - Clinical …, 2016 - Springer
Background ENCORE1 demonstrated non-inferiority of daily efavirenz 400 mg (EFV400)
versus 600 mg (EFV600) to 96 weeks in treatment-naïve, HIV-infected adults but concerns …
versus 600 mg (EFV600) to 96 weeks in treatment-naïve, HIV-infected adults but concerns …
Population pharmacokinetic modeling of the association between 63396C→ T pregnane X receptor polymorphism and unboosted atazanavir clearance
A Schipani, M Siccardi, A D'Avolio… - Antimicrobial agents …, 2010 - Am Soc Microbiol
Atazanavir (ATV) plasma concentrations are influenced by CYP3A4 and ABCB1, which are
regulated by the pregnane X receptor (PXR; NR1I2). PXR expression is correlated with …
regulated by the pregnane X receptor (PXR; NR1I2). PXR expression is correlated with …